Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes - Rastogi, P; O'Shaughnessy, J; Martin, M (J Clin Oncol, 2024)
Erratum in: J Clin Oncol. 2024 Jun 10;42(17):2111. doi: 10.1200/JCO.24.00711. PMID: 38194616; PMCID: PMC10950161